First Lab-in-a-Briefcase to Boost Global Early Diagnosis of Cancer
|
By LabMedica International staff writers Posted on 18 Nov 2015 |

Image: The 4 main components of the newly developed “lab-in-a-briefcase.” (1) Disposable multiple syringe aspirator (MSA) devices, each of which can perform 10 replicate ELISA tests on each of the 8 samples. (2) Customized microwell plates preloaded with reagents that interface with the MSA. (3) Portable USB-powered film scanner for colorimetric signal quantification. (4) Portable computer for real-time data analysis (Photo courtesy of Barbosa AI et al., 2015, and the journal Lab on a Chip.)
To help boost early cancer detection rates worldwide, scientists have developed an all-in-one portable mini-laboratory for point-of-care cancer screening, rapid detection, and monitoring. The prototype successfully tested for prostate cancer, and can operate at even at high temperatures often found in remote areas without air-conditioned clinics.
An estimated 70% of the world’s cancer deaths occur in Africa, Asia, and Central and South America. The lab-in-a-briefcase, believed to be a first-of-its-kind, was developed by a team from Loughborough University (Leicestershire, UK) and Capillary Film Technology, Ltd. (West Sussex,UK), led by Dr. Nuno Reis, lecturer in chemical engineering, Loughborough University.
One of the system’s remarkable features is the use whole blood without the need for sample preparation, which has been a challenging task for settings outside of a central laboratory. This also provides improved safety by minimizing the handling of blood samples from patients that may have infectious diseases.
The compact system, a complete miniaturized ELISA platform, comprises of 4 main components: a manually driven multi-syringe aspirator capable of performing up to 80 simultaneous tests from whole blood samples; microwell ELISA plates pre-loaded with assay reagents; a portable USB-powered film scanner to image test-strips; and a portable computer for real-time data analysis.
The easy-to-use, semi-automated system requires only one operator with minimal training to conduct the test within 15 minutes – with no need for additional equipment or instruments.
A new affordable, disposable microfluidic test-strip—comprising of tiny capillary tubes about the width of a human hair—is used specifically for quick measurement of different cancer biomarkers in a whole blood sample. This technology, which operates like a pregnancy test, has already been used successfully in a separate study led by Dr. Reis that detected prostate cancer with the help of a smartphone camera. The new, lab-in-a-briefcase study also focused on detecting prostate cancer (by testing for the PSA [prostate-specific antigen] biomarker); however the microfluidic test-strip is versatile enough to measure several cancer biomarkers simultaneously from a single sample.
“Our lab-in-a-briefcase is both inexpensive and simple to use; it means that high-precision diagnostic kits, complete with clinical laboratory equipment, can be made accessible to remote populations, and this is what makes it a truly life-changing concept for the screening and monitoring of different types of cancer,” said
Dr. Reis, “This portable lab can really make a difference, boosting levels of cancer detection in developing countries where ordinarily people would not have such easy access to early diagnostics. I envisage that our lab-in-a-briefcase could also be developed further in the future to allow for rapid testing of infectious diseases and allergens.”
The study, by Barbosa AI et al, was published in June, 2015, in the journal Lab on a Chip.
Related Links:
Loughborough University
Capillary Film Technology
An estimated 70% of the world’s cancer deaths occur in Africa, Asia, and Central and South America. The lab-in-a-briefcase, believed to be a first-of-its-kind, was developed by a team from Loughborough University (Leicestershire, UK) and Capillary Film Technology, Ltd. (West Sussex,UK), led by Dr. Nuno Reis, lecturer in chemical engineering, Loughborough University.
One of the system’s remarkable features is the use whole blood without the need for sample preparation, which has been a challenging task for settings outside of a central laboratory. This also provides improved safety by minimizing the handling of blood samples from patients that may have infectious diseases.
The compact system, a complete miniaturized ELISA platform, comprises of 4 main components: a manually driven multi-syringe aspirator capable of performing up to 80 simultaneous tests from whole blood samples; microwell ELISA plates pre-loaded with assay reagents; a portable USB-powered film scanner to image test-strips; and a portable computer for real-time data analysis.
The easy-to-use, semi-automated system requires only one operator with minimal training to conduct the test within 15 minutes – with no need for additional equipment or instruments.
A new affordable, disposable microfluidic test-strip—comprising of tiny capillary tubes about the width of a human hair—is used specifically for quick measurement of different cancer biomarkers in a whole blood sample. This technology, which operates like a pregnancy test, has already been used successfully in a separate study led by Dr. Reis that detected prostate cancer with the help of a smartphone camera. The new, lab-in-a-briefcase study also focused on detecting prostate cancer (by testing for the PSA [prostate-specific antigen] biomarker); however the microfluidic test-strip is versatile enough to measure several cancer biomarkers simultaneously from a single sample.
“Our lab-in-a-briefcase is both inexpensive and simple to use; it means that high-precision diagnostic kits, complete with clinical laboratory equipment, can be made accessible to remote populations, and this is what makes it a truly life-changing concept for the screening and monitoring of different types of cancer,” said
Dr. Reis, “This portable lab can really make a difference, boosting levels of cancer detection in developing countries where ordinarily people would not have such easy access to early diagnostics. I envisage that our lab-in-a-briefcase could also be developed further in the future to allow for rapid testing of infectious diseases and allergens.”
The study, by Barbosa AI et al, was published in June, 2015, in the journal Lab on a Chip.
Related Links:
Loughborough University
Capillary Film Technology
Latest Technology News
- AI-Powered Biomarker Predicts Liver Cancer Risk
- Robotic Technology Unveiled for Automated Diagnostic Blood Draws
- ADLM Launches First-of-Its-Kind Data Science Program for Laboratory Medicine Professionals
- Aptamer Biosensor Technology to Transform Virus Detection
- AI Models Could Predict Pre-Eclampsia and Anemia Earlier Using Routine Blood Tests
- AI-Generated Sensors Open New Paths for Early Cancer Detection
- Pioneering Blood Test Detects Lung Cancer Using Infrared Imaging
- AI Predicts Colorectal Cancer Survival Using Clinical and Molecular Features
- Diagnostic Chip Monitors Chemotherapy Effectiveness for Brain Cancer
Channels
Clinical Chemistry
view channel
Rapid Blood Testing Method Aids Safer Decision-Making in Drug-Related Emergencies
Acute recreational drug toxicity is a frequent reason for emergency department visits, yet clinicians rarely have access to confirmatory toxicology results in real time. Instead, treatment decisions are... Read more
New PSA-Based Prognostic Model Improves Prostate Cancer Risk Assessment
Prostate cancer is the second-leading cause of cancer death among American men, and about one in eight will be diagnosed in their lifetime. Screening relies on blood levels of prostate-specific antigen... Read moreMolecular Diagnostics
view channel
AI-Powered Liquid Biopsy Classifies Pediatric Brain Tumors with High Accuracy
Liquid biopsies offer a noninvasive way to study cancer by analyzing circulating tumor DNA in body fluids. However, in pediatric brain tumors, the small amount of ctDNA in cerebrospinal fluid has limited... Read more
New CSF Liquid Biopsy Assay Reveals Genomic Insights for CNS Tumors
Central nervous system (CNS) malignancies pose distinctive diagnostic challenges because tissue-based testing is often infeasible and the blood–brain barrier limits the usefulness of plasma liquid biopsy.... Read more
Group A Strep Molecular Test Delivers Definitive Results at POC in 15 Minutes
Strep throat is a bacterial infection caused by Group A Streptococcus (GAS). It is a leading bacterial cause of acute pharyngitis, particularly in children and adolescents, and one of the most common reasons... Read more
Rapid Molecular Test Identifies Sepsis Patients Most Likely to Have Positive Blood Cultures
Sepsis is caused by a patient’s overwhelming immune response to an infection. If undetected or left untreated, sepsis leads to tissue damage, organ failure, permanent disability, and often death.... Read moreHematology
view channel
Rapid Cartridge-Based Test Aims to Expand Access to Hemoglobin Disorder Diagnosis
Sickle cell disease and beta thalassemia are hemoglobin disorders that often require referral to specialized laboratories for definitive diagnosis, delaying results for patients and clinicians.... Read more
New Guidelines Aim to Improve AL Amyloidosis Diagnosis
Light chain (AL) amyloidosis is a rare, life-threatening bone marrow disorder in which abnormal amyloid proteins accumulate in organs. Approximately 3,260 people in the United States are diagnosed... Read moreImmunology
view channel
New Biomarker Predicts Chemotherapy Response in Triple-Negative Breast Cancer
Triple-negative breast cancer is an aggressive form of breast cancer in which patients often show widely varying responses to chemotherapy. Predicting who will benefit from treatment remains challenging,... Read moreBlood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug
Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more
Whole-Genome Sequencing Approach Identifies Cancer Patients Benefitting From PARP-Inhibitor Treatment
Targeted cancer therapies such as PARP inhibitors can be highly effective, but only for patients whose tumors carry specific DNA repair defects. Identifying these patients accurately remains challenging,... Read more
Ultrasensitive Liquid Biopsy Demonstrates Efficacy in Predicting Immunotherapy Response
Immunotherapy has transformed cancer treatment, but only a small proportion of patients experience lasting benefit, with response rates often remaining between 10% and 20%. Clinicians currently lack reliable... Read moreMicrobiology
view channel
Rapid Test Promises Faster Answers for Drug-Resistant Infections
Drug-resistant pathogens continue to pose a growing threat in healthcare facilities, where delayed detection can impede outbreak control and increase mortality. Candida auris is notoriously difficult to... Read more
CRISPR-Based Technology Neutralizes Antibiotic-Resistant Bacteria
Antibiotic resistance has accelerated into a global health crisis, with projections estimating more than 10 million deaths per year by 2050 as drug-resistant “superbugs” continue to spread.... Read more
Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease
Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read morePathology
view channel
AI Tool Uses Blood Biomarkers to Predict Transplant Complications Before Symptoms Appear
Stem cell and bone marrow transplants can be lifesaving, but serious complications may arise months after patients leave the hospital. One of the most dangerous is chronic graft-versus-host disease, in... Read more
Research Consortium Harnesses AI and Spatial Biology to Advance Cancer Discovery
AI has the potential to transform cancer care, yet progress remains constrained by fragmented, inaccessible data that hinder advances in early diagnosis and precision therapy. Unlocking patterns missed... Read moreIndustry
view channel
QuidelOrtho Collaborates with Lifotronic to Expand Global Immunoassay Portfolio
QuidelOrtho (San Diego, CA, USA) has entered a long-term strategic supply agreement with Lifotronic Technology (Shenzhen, China) to expand its global immunoassay portfolio and accelerate customer access... Read more







